SERENA-6
What it tests: 1L camizestrant for emergent ESR1 mutations in advanced breast cancer: final PFS2 (phase III)
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.